The Proxy Trade: What Happens When One Company's Hype Inflates Another's Price

Rocket Lab's stock has fallen 57% from its May 2026 peak. The company just reported record revenue growing 62% year-over-year. The CEO signed an $8 billion acquisition last month. The business is going stronger than ever.

And the stock has been torn in half.

The disconnect between the fundamentals and the price is the story here. Not whether the "space trade" is hot or cold, but why Rocket Lab's shares rose so far above what the business could justify—and what a 57% correction tells us about how the market prices companies that exist in someone else's shadow.

Here is the picture most investors carry around: Rocket Lab is the publicly traded SpaceX. You can't buy SpaceX before mid-June 2026, so you buy Rocket Lab instead. When SpaceX goes public and explodes upward, Rocket Lab rides along. The company is smaller, but the thesis is the same—rockets, satellites, the new space economy.

The part that picture deletes is that a proxy trade is not a business investment. It is a bet on capital flowing from one ticker to another. And proxy trades have a clock that has nothing to do with earnings.

Put away the acronyms for thirty seconds. Think about a crowded restaurant with two tables. The headliner chef—let's call her Elena—has a waiting list. You can't get a reservation. But there's another restaurant on the same block, run by Marco, who makes similar food. People who want to be near Elena start sitting at Marco's. Marco's prices go up, not because Marco improved, but because everyone is treating his table as a stand-in for Elena's.

Then Elena finally opens her own restaurant. The crowd splits. Some people stay at Marco's because they genuinely like his food. Most leave because they were never dining there—they were waiting for Elena.

Marco's check average doesn't change. His rent doesn't change. But the people counting the seats at his table suddenly realize they've been paying headliner prices for a solid-but-different operation.

Now label the props.

• Elena is SpaceX.
• Marco is Rocket Lab.
• The "similar food" is the shared industry—rocket launches, satellite deployment, space infrastructure.
• The price inflation at Marco's is RKLB's multiple expansion through 2025 and into 2026, driven by investors who wanted space exposure before SpaceX was publicly tradable.
• The clock is the SpaceX IPO. Before it, Rocket Lab was the only way to bet big on a launch company in a standard brokerage account. After June 12, 2026, it wasn't.

The numbers make the mechanism visible.

SpaceX IPO'd on June 12, 2026, raising about $75 billion at roughly a $1.75 trillion valuation. The stock briefly climbed toward $226, pushing market value above $2.9 trillion. It has since settled near $148, still close to its $135 IPO price. The initial frenzy drained and the stock normalized.

Rocket Lab peaked at $151 in late May 2026—weeks before SpaceX went public. The stock is now around $62. A 57% decline.

In the toy version, Marco's stock price should have moved with Marco's revenue. But Marco's revenue kept climbing: $200 million in Q1 2026, up 63.5% year-over-year, then $234 million in Q2, up 62%. The quarterly run rate points toward roughly $940 million annually. The company signed an $8 billion deal to acquire Iridium Communications in late June, adding a live satellite constellation, spectrum rights, and recurring revenue.

None of that changed during the sell-off. The business improved. The price collapsed. Because the price was not anchored to the business. It was anchored to Elena's opening night.

Here is where the analogy breaks.

A proxy trade and a business are not interchangeable once the proxy is no longer needed. But Rocket Lab is not merely a placeholder. It is a real company with two operating segments—launch services and space systems—that generated $234 million in a single quarter last year. It carries $2.1 billion in cash, only $695 million in debt, and a net cash position of roughly $2.3 billion. The balance sheet is not fragile.

The problem is not the business. The problem is the multiple that the market piled onto it.

At its $151 peak, Rocket Lab's market cap was roughly $90 billion. Today at $62, it sits around $37 billion. That $37 billion implies a price-to-sales multiple of 48 times trailing revenue. For comparison, SpaceX—actually Elena—trades at roughly 85 times sales on a $1.95 trillion market cap. Rocket Lab is not cheap. It is simply 57% less expensive than it was.

Both companies are deeply loss-making. Rocket Lab burned $371 million in free cash flow over the trailing twelve months. SpaceX posted a $4.28 billion net loss in Q1 2026 alone. Valuation multiples on negative earnings tell you nothing about profit—they only tell you how much future revenue the market has already paid for, before that revenue exists.

The $8 billion Iridium acquisition changes the mechanism. Rocket Lab said the deal is "significantly accretive to cash flow generation and profitability". Iridium brings 66 low-Earth-orbit satellites, irreplaceable L-band spectrum, and an existing customer base that generates recurring revenue. It transforms Rocket Lab from a launch-and-manufacture company into a full-stack operator with its own live constellation.

That is the kind of move that should be priced on its own terms: what does the combined company earn, when does Neutron—the reusable medium-lift rocket targeted for Q4 2026—start flying, and does the integration actually produce the accretion Rocket Lab promises? Those are business questions. They are not answered by whether SpaceX's stock goes up or down next week.

The stock's trajectory since May has been a correction, not a verdict. The proxy trade unwound when the original reference point became directly available. What remains underneath is a company with accelerating revenue, a fat cash pile, a massive acquisition still in process, and a rocket that has not yet flown.

Bring the model back to the stock.

If you are watching Rocket Lab, the question is no longer "What does SpaceX do to this stock?" That mechanism has already fired. The question is whether $37 billion is a reasonable price for a company earning $900 million a year in revenue, spending $371 million a year in free cash, and in the middle of an $8 billion acquisition whose integration timeline is unproven.

The 48x revenue multiple says the market expects something extraordinary. That is not the same as saying something extraordinary will happen. Revenue growth of 60%+ is real. But multiples compress when the catalyst that inflated them disappears—and the SpaceX IPO was that catalyst for a meaningful portion of Rocket Lab's holders.

If you remember one test, use this one: separate the proxy from the business. Watch the Iridium integration, the Neutron first flight, and the path from $940 million annualized revenue to actual cash-flow positivity. Those are the numbers that determine whether this stock is a company or a memory of a trade.

The warning is simple: a 57% decline does not make a stock "on sale" if the original price was built on a story that is no longer the story. Marco's restaurant was never Elena's. It just looked similar enough from the street.